Endosense Completes CHF 26 Million ($20 Million) Fundraising Backed By 3i And NeoMed

Endosense, an emerging cardiovascular device company, today announced the closing of a CHF 26 million (USD 20 million) financing with 3i and NeoMed. Endosense, set up in 2003, is developing a Force Sensor ablation catheter for use in the field of cardiac arrhythmia.

Back to news